COMPANY PROFILE

Passkey Therapeutics

Explore full profile

Discovering new medicines by unlocking rational polypharmacology

Cambridge, United StatesFounded 2023Biotech & Life Sciences

Valuation $100–250M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Passkey Therapeutics

Metabolic Passkey Therapeutics is dedicated to the discovery of new medicines targeting complex diseases with multifactorial causes. The company operates in the pharmaceutical sector, focusing on metabolic diseases such as lipid disorders, obesity, and diabetes, as well as various forms of cancer. Utilizing a Rational Polypharmacology platform, Passkey leverages recent advances in computational and genomic methods to develop novel therapeutics. The business model centers on creating drugs that address the intricate interplay of biological pathways influenced by genetics and the environment. By targeting the molecular and cellular mechanisms of disease, Passkey aims to produce treatments with superior efficacy and fewer side effects compared to conventional therapies. The company serves healthcare providers and patients affected by these widespread and inadequately treated conditions.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2023
Headquarters: Cambridge, United States
Employees: 8
Open positions: None listed
Dealroom signal: 56.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Medical Research, Medical & Healthcare, Research and Development, Biotech and Pharma, Rare Diseases, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Oct 2024	$20M	$80M	Wireframe Ventures · Innovation Endeavors · Alexandria Venture Investments · GRIDS Capital	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Passkey Therapeutics website traffic

Latest recorded traffic for Passkey Therapeutics is 1K monthly website visits, up 63.9% over the last three months. Passkey Therapeutics's team declined 20% over the past year.

Latest monthly visits1K 3-month web change+63.9% 1-year team growth-20%

Monthly website visitsJan 2024–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CPCentessa PharmaceuticalsMerger of ten pharmaceutical companies developing drugs for sleep-wake disorders, neurological conditions and cancer	Boston, United States	Acquired	161	$250M	$6.1B
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational
PRProfionicsInnovative diagnostic solutions leveraging biomarkers and AI to rapidly detect and treat sepsis	Stevenage, United Kingdom	Operational
EBEXO BiologicsNovel nanomedicine platform for rare disease therapeutics	Liège, Belgium	Operational
MOMoleculeaiAI driven drug-discovery platform that uses deep learning and generative modeling to radically shorten the time and cost of discovering new therapeutic molecules	New Delhi, India	Acquired
ICInnox Corp.Botanical products enhancing patient outcomes with FDA-aligned solutions	Mahwah, United States	Operational
GTGluBio TherapeuticsEngages in molecular glue-targeted protein degradation drug discovery	China	Operational
VTVasa TherapeuticsPrecision medicine for heart failure and healthy aging	Encinitas, United States	Operational